Pfizer taps Dewpoint Therapeutics in $239M dystrophy drug deal
| Authors | Ben Adams |
|---|---|
| Published | January 6, 2021 |
| Keywords | |
| Source | View at FierceBiotech |
Fierce 15 winner Dewpoint Therapeutics has added Pfizer to its growing list of pharma partners looking to tap the startup’s next-gen approach to a host of diseases.
The U.S.-German biotech is working on condensates, a new area of research that is helping explain aspects of cell biology that have been mysterious to researchers…
Join the conversation